Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical (Nasdaq: COLL) announced acceptance of seven ADHD research abstracts for presentation at two upcoming scientific congresses. Presentations are scheduled for the AACAP Annual Meeting, October 26–31, 2026, in Atlanta, and the NEI Fall Congress, November 5–8, 2026, in Colorado Springs.
The research includes pediatric Phase 4 studies of AZSTARYS, including a study in children aged 4–5 years, and retrospective JORNAY PM analyses examining treatment persistence and morning functioning in adults. Other presentations address clinical response patterns and caregiver strain. The real-world analyses are observational, and investigators describe their findings as hypothesis-generating.
Collegium Pharmaceutical (COLL) launched Start Talking ADHD, an online resource hub for people with attention-deficit/hyperactivity disorder and their families.
The hub offers three downloadable guides for conversations with healthcare providers, schools and support networks. The Doctor Discussion Guide helps users document experiences throughout a typical day before an appointment. The educational guide explains 504 Plans and Individualized Education Programs, two pathways for school support, and includes an evaluation overview and preparation checklist. The community guide helps users map their support networks and find relevant organizations. These resources are educational; they do not diagnose ADHD or recommend specific treatments. Collegium added a second ADHD medicine to its portfolio in May 2026.
Collegium Pharmaceutical (COLL) will participate in two upcoming investor conferences in New York. Management joins the Morgan Stanley 24th Annual Global Healthcare Conference for a fireside chat on September 15, 2026, at 4:05 p.m. ET, and presents at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 9:00 a.m. ET. Live webcasts and 90-day replays of both events will be accessible through the Investors section of the company’s website.
Collegium (Nasdaq: COLL) entered a $50 million Accelerated Share Repurchase (ASR) agreement with Jefferies to buy back its common stock, under the $150 million repurchase program authorized in July 2025. After this ASR, $100 million will remain available under the broader program.
Collegium will pay $50 million and receive an initial 1,556,420 shares, calculated using the $25.70 closing price on August 12, 2026, representing about 80% of the total shares expected under the ASR. The final number of shares will be based on volume-weighted average prices during the ASR term, with settlement expected by the fourth quarter of 2026. As of June 30, 2026, Collegium reported 32.5 million shares outstanding.
Collegium (Nasdaq: COLL) reported second quarter 2026 product revenues, net of $199.9 million, up 6% year-over-year, driven by its ADHD franchise and partially offset by pain portfolio declines. JORNAY PM® net revenue rose 41% to $46.1 million, while newly acquired AZSTARYS® contributed $12.9 million from May 12 to June 30.
Pain portfolio net revenues were $140.9 million, down 9% year-over-year, with Belbuca® up 10%, Xtampza® ER down 14% and Nucynta franchise down 24%. Collegium completed the AZSTARYS acquisition, recorded GAAP net loss of ($15.1) million versus prior-year GAAP net income of $12.0 million, but grew non-GAAP adjusted net income to $75.4 million and adjusted EBITDA to $113.8 million (up 8%).
Full-year 2026 guidance was updated: product revenues, net reduced to $825–$855 million from $865–$895 million, AZSTARYS revenue, net raised to $65–$75 million, JORNAY PM guidance reaffirmed, and adjusted EBITDA lowered to $445–$470 million. The company generated $71.3 million in operating cash and ended the quarter with $129.5 million in cash, cash equivalents and marketable securities.
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report its second quarter 2026 financial results before the U.S. market opens on Thursday, August 6, 2026. Immediately afterward, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results.
Investors can join the call by dialing (877) 407-8037 in the U.S. or (201) 689-8037 internationally and referencing the “Collegium Pharmaceutical Q2 2026 Earnings Call.” A live and replay webcast will be available in the Investors section of www.collegiumpharma.com, with replay access beginning approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027. The move is described by the company as aligned with its evolution as a diversified biopharmaceutical business.
According to Collegium, the Boston location embeds the company within a major healthcare and life sciences hub and supports future growth, collaboration and its long-term commitment to Massachusetts, where it was founded. One Lincoln is owned and managed by DivcoWest, and Avison Young acted as Collegium's real estate advisor.
Collegium Pharmaceutical (Nasdaq: COLL) announced inducement equity grants made on June 1, 2026 under its 2026 Inducement Plan. The company granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees, with three-year, service-based vesting, under Nasdaq Listing Rule 5635(c)(4).
Collegium (Nasdaq: COLL) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The session is scheduled for Wednesday, June 3, 2026, at 1:20 p.m. ET, with a live webcast and 90-day replay on the company’s investor website.
Collegium (Nasdaq: COLL) completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million in cash, plus up to $135 million in milestone payments. The deal is funded by $350 million cash and a $300 million term loan.
Collegium raised 2026 guidance, now expecting total product revenues, net of $865–$895 million and adjusted EBITDA of $475–$500 million, including $60–$70 million AZSTARYS revenue and >$50 million run-rate synergies within 12 months. AZSTARYS has patent protection expected through 2037. The company also announced upcoming departures of its Chief Commercial Officer and Chief Medical Officer in 2026.